Core Viewpoint - The leading domestic hyaluronic acid company, Huaxi Biological, has publicly criticized 10 research reports from 9 securities firms for containing misleading statements, highlighting the competitive dynamics between hyaluronic acid and recombinant collagen products [1][2][3] Group 1: Criticism of Research Reports - Huaxi Biological published a nearly 5000-word article accusing the reports of creating inflated expectations around recombinant collagen products at the expense of the hyaluronic acid industry [2][3] - The criticized reports include those from major firms such as Huatai Securities, Ping An Securities, and Western Securities, with specific claims of bias and contradictions in their analyses [3][5][12] - Some reports have been reportedly deleted, particularly the one from Western Securities, raising questions about the integrity of the research [5][22] Group 2: Market Dynamics and Product Comparison - The reports discussed the advantages and disadvantages of hyaluronic acid and recombinant collagen, with some showing a preference for collagen, which has led to concerns about the objectivity of the analyses [7][16] - Huaxi Biological's core product is hyaluronic acid, while the competitor, Juzhi Biological, focuses on recombinant collagen, both of which are used in medical and cosmetic applications [3][19] - The market for recombinant collagen is expected to grow rapidly, potentially surpassing that of hyaluronic acid, due to its higher technical barriers and product characteristics [20][19] Group 3: Analyst Reactions and Industry Implications - The incident has sparked discussions among analysts, with some suggesting that securities firms may feel pressured to remain silent due to their weaker position against prominent companies like Huaxi Biological [23][22] - Analysts have noted that while both products have their merits, the technical complexity of recombinant collagen is higher than that of hyaluronic acid, reflecting broader trends in consumer preferences [23][20] - Despite the criticism, several securities firms continue to issue positive ratings for Huaxi Biological, indicating a complex relationship between market perception and research integrity [22][19]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In 2024, the company achieved operating revenue of 5.37 billion yuan, a year-on-year decline of 11.6%, and a net profit attributable to shareholders of 170 million yuan, down 70.6% year-on-year. In Q4 2024, the operating revenue was 1.5 billion yuan, a decrease of 19.3% year-on-year, with a net profit of -190 million yuan [2][4]. - For Q1 2025, the company reported operating revenue of 1.08 billion yuan, a year-on-year decline of 20.8%, and a net profit of 100 million yuan, down 58.1% year-on-year [2][4]. - The company is focusing on overall resource efficiency and is undergoing a phase of adjustment in its skincare business, while the raw material business is growing steadily, and the high-margin medical terminal business is expanding rapidly [9]. Summary by Sections Financial Performance - In 2024, the raw material business generated revenue of 1.24 billion yuan, up 9.5% year-on-year, with international market expansion showing a growth of 17.7%, particularly in the Americas, Europe, and Southeast Asia, where growth exceeded 20% [9]. - The medical terminal business achieved revenue of 1.44 billion yuan, a year-on-year increase of 32%, with skin-related medical products growing by 43.6% [9]. - The functional skincare business reported revenue of 2.57 billion yuan, down 31.6% year-on-year, while the nutritional science business generated 80 million yuan, up 41% year-on-year [9]. Cost and Profitability - The company's gross margin improved by 0.8 percentage points year-on-year, with the raw material, medical terminal, and functional skincare gross margins changing by 0.9, 2.3, and -1.1 percentage points respectively [9]. - The net profit margin decreased by 6.5 percentage points year-on-year due to increased management expenses and changes in the organizational structure [9]. Future Outlook - The company is expected to see improvements in revenue and profit as it continues to adjust its skincare business and launch new products. The raw material business is expected to maintain a strong market position, and the medical beauty business is gradually contributing more to overall performance [9]. - EPS forecasts for 2025-2027 are 0.95, 1.33, and 1.67 yuan per share respectively [9].

【要闻报道】 英伟达拟再推"中国特供"芯片 据参考消息援引新加坡《联合早报》网站5月25日引述路透社消息报道，美国芯片巨头英伟达据报将为 中国市场推出一款基于Blackwell架构的人工智能（AI）芯片，售价将大幅低于先前的H20芯片，预计最 快于6月开始量产。 报道称，这款采用最新一代Blackwell架构的AI处理器，预计售价介于6500美元至8000美元之间，明显 低于H20的定价。较低的售价通常意味着芯片规格相对较弱，制造工艺也更为简化。 点评：这将是英伟达第三次为中国市场推出符合美国监管要求的降级版芯片。美国政府日前禁止英伟达 向中国销售基于Hopper架构的H20芯片。 特朗普威胁50%关税两天后改口：恢复与欧盟贸易谈判窗口期 美国总统特朗普在与欧盟委员会主席冯德莱恩通电话后表示，他将把欧盟面临50%关税的最后期限延长 至7月9日。 特朗普当地时间周日在返回华盛顿的途中对记者说："我们进行了一次非常愉快的通话，我同意将它撤 回。" 冯德莱恩稍早前在X上发文称，"欧洲已准备好迅速、果断地推进谈判"，但"达成一项好的协议需要时 间，直到7月9日"。那是特朗普暂停所谓对等关税90天的截止日。 点评：这次 ...

Core Viewpoint - The article discusses the controversy surrounding Huaxi Biological, a leading player in the medical aesthetics industry, which publicly refuted claims made by nine brokerage firms regarding the obsolescence of hyaluronic acid, asserting that these claims mislead the market and harm the industry [2][5][13]. Group 1: Industry Response - Huaxi Biological received support from two industry associations before making its statement and has reported the misleading content to the China Securities Regulatory Commission (CSRC) [2][12]. - Following Huaxi's public rebuttal, some brokerage firms have deleted their reports, and certain institutions have issued apologies to the company [2][12]. - The brokerage reports in question were primarily focused on the emerging concept of recombinant collagen, which Huaxi argues is being promoted at the expense of hyaluronic acid [5][13]. Group 2: Misleading Claims - Huaxi Biological criticized the brokerage reports for making misleading comparisons between hyaluronic acid and recombinant collagen, claiming that these reports lacked scientific basis and were driven by speculative capital [5][13]. - The company highlighted that the reports suggested hyaluronic acid was inferior to recombinant collagen in terms of safety and efficacy, which Huaxi disputes, stating that such conclusions are not supported by scientific evidence [5][31]. Group 3: Regulatory and Compliance Issues - The article raises concerns about the compliance of the brokerage reports, suggesting that they may not have adhered to the necessary standards for objectivity and scientific backing [20][21]. - Industry experts indicate that the reports should have included relevant data to support their claims, and the lack of such data could lead to regulatory scrutiny [21][22]. - The ongoing regulatory environment is described as increasingly stringent, with past instances of penalties for brokerage firms due to similar issues [26][27]. Group 4: Scientific Basis of Claims - Huaxi Biological argues that both hyaluronic acid and recombinant collagen have their unique applications and benefits, and it is inappropriate to declare one superior to the other without substantial scientific evidence [31][32]. - The company emphasizes that the existing research favors hyaluronic acid in certain applications, particularly in skin hydration and immediate filling, while recombinant collagen may have advantages in tissue repair [31][32].

Core Viewpoint - The article discusses the controversy surrounding Huaxi Biological's rebuttal of the claims made by nine brokerage firms regarding hyaluronic acid being "outdated" and the promotion of recombinant collagen as a superior alternative, highlighting the impact of these claims on the market and the industry [2][4][9]. Group 1: Company Actions - Huaxi Biological publicly refuted the claims about hyaluronic acid and named nine brokerage firms for misleading reports, which has led to some brokerages retracting their reports and issuing apologies [2][8]. - The company received support from two industry associations before making its statement and has reported the matter to the China Securities Regulatory Commission [2][8]. - As of May 23, three of the ten reports mentioned have been removed from public access, while the remaining seven are still available for viewing [8][9]. Group 2: Industry Context - The medical beauty industry is characterized by a high overlap between capital market participants and enterprise users, making capital evaluations significantly impactful on the competitive landscape, which explains Huaxi Biological's strong response [2][4]. - The article emphasizes that the claims made in the brokerage reports lack scientific basis and are driven by speculative capital, which could harm a key industry in China [6][9][24]. Group 3: Scientific Claims - Huaxi Biological argues that the reports promoting recombinant collagen over hyaluronic acid are misleading and lack substantial scientific evidence, asserting that both substances have their unique benefits and should not be directly compared [23][24]. - The company highlights that the regulatory approvals for hyaluronic acid products far exceed those for recombinant collagen, indicating a stronger safety profile for hyaluronic acid [25][26]. Group 4: Regulatory Environment - The article notes that the regulatory environment for brokerage reports is tightening, with recent inspections revealing issues in compliance and the need for better management of report quality and information sources [18][20]. - There is a growing concern about the potential for misleading information in brokerage reports, which could lead to regulatory actions against the firms involved if found to be in violation of established guidelines [21][22].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a steady recovery in social consumption, with April 2025 retail sales showing a year-on-year increase of 5.1%, and a total retail sales amount of 1618.45 billion yuan for the first four months of 2025, reflecting a 4.7% year-on-year growth [4][25] - The report suggests that the overall social consumption is expected to maintain stable growth due to effective policy measures aimed at boosting domestic demand, with a focus on the high-growth segments of gold jewelry and cosmetics [4][31] Summary by Sections Retail Market Overview - The retail industry index closed at 2110.59 points, down 1.61% for the week, underperforming the Shanghai Composite Index, which fell by 0.57% [6][15] - The jewelry sector showed the highest growth among retail segments, with a weekly increase of 7.56% and a year-to-date increase of 18.83% [17][20] Social Consumption Trends - In April 2025, the retail sales of consumer goods increased by 5.1%, driven by favorable consumption policies and the Qingming holiday effect [28][31] - Online retail sales for the first four months of 2025 reached 4741.9 billion yuan, growing by 7.7%, with physical goods online retail accounting for 24.3% of total retail sales [28][29] Investment Recommendations - Investment focus on high-growth segments under emotional consumption themes, particularly in gold jewelry and cosmetics [7][39] - Recommended companies in the gold jewelry sector include Laopuhuangjin, Chaohongji, and Zhou Dasheng, which are expected to benefit from differentiated product offerings and consumer insights [39][41] - In the cosmetics sector, recommended brands include Proya, Shangmei, and Juzi Biological, which are positioned to capitalize on the ongoing trend of domestic brand growth [39][41] Company Performance Highlights - Proya reported a 28.9% year-on-year increase in net profit for Q1 2025, driven by new product launches [40] - Chaohongji achieved a 25.4% year-on-year revenue growth in Q1 2025, indicating strong brand momentum [40] - Zhou Dasheng's revenue for Q1 2025 was down 47.3% year-on-year, highlighting challenges in the current market environment [40]

Investment Rating - The report indicates a strong growth potential for the hyaluronic acid underwear industry, with a projected market size increase from 1 billion to 10.4 billion yuan from 2022 to 2024, reflecting a compound annual growth rate (CAGR) of over 300% [29][32]. Core Insights - The rapid development of the hyaluronic acid underwear market is driven by technological advancements and innovation, particularly in integrating hyaluronic acid into textiles for enhanced moisturizing properties [2][4]. - Consumer awareness and demand for functional and aesthetically pleasing clothing are significant growth drivers, with a notable shift towards products that offer both warmth and skin benefits [3][40]. - The market faces challenges such as product homogenization, leading to intensified brand competition and a focus on product differentiation and technological innovation as core strategies for future growth [3][34]. Summary by Sections Industry Overview - Hyaluronic acid is recognized for its natural safety and biodegradability, making it a key ingredient in the development of moisturizing functional textiles [15][22]. - The market for hyaluronic acid underwear is characterized by a transition from basic thermal properties to dual benefits of warmth and skin care [4][22]. Market Size - The market size for hyaluronic acid underwear is expected to grow from 14.5 billion yuan in 2025 to 25.3 billion yuan by 2029, maintaining a stable upward trend despite a slowdown in growth rate [29][32]. Driving Factors - The growth of the hyaluronic acid underwear industry is supported by favorable policies that promote innovation and market expansion, aligning with trends towards health and sustainability [26][27]. Competitive Landscape - The online retail market for hyaluronic acid underwear shows significant concentration, with leading brands like Qiaolaiti dominating in market share and consumer recognition [35][34]. - The competitive environment is marked by a reliance on digital platforms for sales, particularly Douyin, which accounts for over 80% of sales in this segment [35][34]. Consumer Demand - There is a growing consumer preference for functional, stylish, and versatile clothing, with significant interest in the moisturizing benefits of hyaluronic acid products [40][42]. - The search index for keywords related to hyaluronic acid underwear on platforms like Douyin has shown substantial growth, indicating strong market potential and consumer interest [42][32].

Core Viewpoint - The company is advancing its product offerings in the field of ergothioneine, with significant developments in both raw materials and functional skincare products [1] Group 1: Product Development - The company’s food-grade ergothioneine is set to receive Self-GRAS certification in the U.S. by 2024 [1] - The company has launched Bioyouth™-EGT Pro and Bioyouth™-EGT Pure, with full production capacity at a tonnage level, and raw material sales have exceeded one million [1] Group 2: Industry Standards - The company has led the drafting of the group standard for high-purity ergothioneine in cosmetics, which was officially implemented in September 2023 [1] Group 3: Nutritional Science Innovation - The company focuses on four core areas and has developed a product matrix around key raw materials such as hyaluronic acid, ergothioneine, rhodiola rosea glycosides, and GABA [1] - Oral ergothioneine products are now available on Tmall through the company’s flagship store, utilizing cross-border e-commerce for sales [1]

券商研报被上市公司"点名"风波延续。5月21日晚，近期处于市场关注焦点的华熙生物再发一文，就5月17日的发文内容做进一步解释，并再度提及 券商研报。回顾此前，华熙生物一次性点名华泰证券、西部证券、国金证券等多家券商研报，并直指其中存在误导性"结论"。有业内人士表示，上 市公司对券商研报的质疑，关键意义在于重新定义上市公司与券商投研的互动关系，从这一角度看，或存在积极意义。对券商研究所而言，未来需 要不断提升专业水平，尽量减少被质疑的可能性。论据专业性、逻辑严谨性是未来研报的核心。 华熙生物再发文 近期，备受市场关注的华熙生物在5月21日再度发文，就此前5月17日的发文内容做进一步解释，也再度提及券商研报内容。 在华熙生物看来，部分券商研报所涉及的企业在医美填充领域并没有获得任何三类医疗器械注册证，所以并不具备对医美填充成分技术的评估和宣 传条件。券商研报中这种B优于A的结论，是缺乏任何公开数据或国内外科研论文结论支持的。 回顾5月17日，华熙生物曾在其官方微信号发文指出，2022年开始，随着资本市场不断追求新的公司题材，重组胶原蛋白概念被看似幸运地选中 了。为了营造比透明质酸产业更大的预期，围绕某重组胶原企业 ...

Core Viewpoint - The recent discussions surrounding hyaluronic acid and recombinant collagen in the medical beauty industry have intensified, particularly following Huaxi Biological's publications defending hyaluronic acid's relevance and efficacy over recombinant collagen [1][4][5]. Group 1: Company Response and Market Dynamics - Huaxi Biological has issued statements refuting claims that hyaluronic acid is outdated, emphasizing the importance of both hyaluronic acid and collagen in skin health, and their interdependent roles in extracellular matrix (ECM) function [4][5]. - The company highlighted that it holds the highest number of approved Class III medical device certifications for hyaluronic acid products, asserting that there is no evidence to suggest that recombinant collagen is safer than hyaluronic acid [5]. - The shift in market focus from hyaluronic acid to recombinant collagen has led to a decline in the stock prices and performance of traditional hyaluronic acid companies, while recombinant collagen firms have seen significant gains [6]. Group 2: Financial Performance - Huaxi Biological reported a revenue decline of 11.61% year-on-year, with total revenue of approximately 5.371 billion yuan and a net profit drop of 70.59%, amounting to about 174 million yuan for 2024 [6][7]. - The company’s medical beauty segment showed positive growth, with raw material business revenue increasing by 9.47% to 1.236 billion yuan, while the medical terminal business grew by 32.03% to 1.44 billion yuan [7]. - The significant decline in overall performance was attributed to challenges in the consumer goods segment, which faced intensified competition and strategic adjustments, resulting in a 31.62% revenue drop to 2.569 billion yuan [7]. Group 3: Management Changes and Corporate Governance - In response to internal issues, Huaxi Biological has initiated a major management reform, focusing on addressing corruption and improving corporate governance, with a strict deadline for employees to report any misconduct [9][10]. - The company has undergone significant personnel changes, including the retirement of senior executives and the appointment of new management to align with strategic development needs [10]. - The management reform aims to correct previous lax practices and establish a more robust operational framework for long-term growth [9].